Not available
Quote | aTyr Pharma Inc. (NASDAQ:LIFE)
Last: | $1.90 |
---|---|
Change Percent: | -0.54% |
Open: | $1.86 |
Close: | $1.90 |
High: | $1.95 |
Low: | $1.82 |
Volume: | 268,406 |
Last Trade Date Time: | 06/04/2024 03:00:00 am |
News | aTyr Pharma Inc. (NASDAQ:LIFE)
2024-06-03 08:19:09 ET More on aTyr Pharma aTyr Pharma, Inc. (LIFE) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on aTyr Pharma Historical earnings data for aTyr Pharma Financial information for aTyr Pharma Read the full arti...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ann...
Message Board Posts | aTyr Pharma Inc. (NASDAQ:LIFE)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $LIFE News Article - aTyr Pharma Announces Achievement of Development Milestone by Part | whytestocks | investorshangout | 02/06/2023 3:25:46 PM |
whytestocks: $LIFE News Article - aTyr Pharma Announces FDA Orphan Drug Designation for Efzofitimod | whytestocks | investorshangout | 04/13/2022 2:55:59 PM |
whytestocks: $LIFE News Article - aTyr Pharma Announces Positive End-of-Phase 2 Meeting with FDA on | whytestocks | investorshangout | 03/10/2022 6:40:52 PM |
whytestocks: $LIFE News Article - Love Hemp Group PLC Announces Directorate Change and Issue of Shar | whytestocks | investorshangout | 02/22/2022 9:45:53 PM |
Top Meme Stock Mentions Money to Move 12/30/2021 $LIFE: | LordTurkeyBaster | investorshub | 12/30/2021 2:00:02 PM |
News, Short Squeeze, Breakout and More Instantly...
SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today ann...
SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the c...
Independent data and safety monitoring board (DSMB) recommends continuation of study without any modifications. Findings further support favorable safety profile of efzofitimod. SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Compa...